Cancer Institute

  • Ingrid Espinoza

    Espinoza Ingrid.2.jpgAssistant Professor, Department of Preventive Medicine

    PhD, Biomedical Sciences, 2002, University of Chile, Santiago, Chile
    Postdoctoral fellow, 2002-04, University of Chile, Santiago, Chile
    Postdoctoral fellow, 2004-08, Northwestern University, Evanston, IL
    Professional Associate in Research, 2008-11, Mayo Clinic, Rochester, MN

    Contact information
    2500 N State St, Room G761
    Jackson, MS 39216
    Phone: (601) 815-3511

    Research interests

    • Identification of molecular biomarkers involved in drug resistance in tumors including colorectal and prostate.
    • Development of combinatorial-targeted therapies for breast cancer

    Research synopsis and clinical work

    Dr. Espinoza is a PhD in Biomedical Sciences and a Clinical Research Certified investigator with expertise in cancer. At UMMC, she has been performing as a translational and clinical cancer investigator and as a clinical operations manager. In these roles, Dr. Espinoza has been responsible for overall management of the development of clinical studies, establishing a collaborative link between basic and clinical researchers in different research areas. Currently, she is a co-investigator in several studies related to cancer, cardiovascular diseases and pharmacology. Her roles on these studies include:

    • Coordinate interdisciplinary activities, lead protocol execution team(s), set goals and establish timelines.
    • Preparation and IRB submission of clinical study protocols, informed consent forms, clinical study reports and other clinical documents as necessary. 
    • Ensure development and execution of activities proposed in the study protocols, including data collection and management using REDCap.
    •  Manage all aspects of study progress to assure adherence to planned timelines and achievement of study goals.
    • Writing and submission of INDs applications.

    In the research area, Dr. Espinoza is focused on the identification of molecular biomarkers involved in drug resistance in tumors including colorectal and prostate, as a way to develop new combinatorial and targeted therapies for cancer patients to improve cancer patients' survival and well-being.

    Recent accomplishments and honors

    • 2016 - Coauthor of the publication selected to feature Issue 117 of JCB. Cover Image, Volume 117, Number 6, June 2016. 
    • 2016- Leadership Award. Office of Faculty Affairs, UMMC. Minority Faculty Professional Development Seminar. September 15-18, 2016 in San Antonio, TX, USA
    • 2017-2017 AACR Minority and Minority-Serving Institution Faculty Scholar in Cancer Research Award. 2017 Annual AACR Meeting, April 1-5 in Washington DC.

    Selected publications

    • The metastasis inducer CCN1 (CYR61) activates the fatty acid synthase (FASN)-driven lipogenic phenotype in breast cancer cells. Menendez JA, Vellon L, Espinoza I, Lupu R. Oncoscience. 2016 Jul 22;3(7-8):242-257. eCollection 2016.
    • Hypoxia on the Expression of Hepatoma Upregulated Protein in Prostate Cancer Cells. Espinoza I, Sakiyama MJ, Ma T, Fair L, Zhou X, Hassan M, Zabaleta J, Gomez CR Front Oncol.;6:144. doi: 10.3389/fonc.2016.00144. eCollection 2016. June 15, 2016
    • Suppression of endogenous lipogenesis induces reversion of the malignant phenotype and normalized differentiation in breast cancer.Gonzalez-Guerrico AM, Espinoza I, Schroeder B, Park CH, Kvp CM, Khurana A, Corominas-Faja B, Cuyàs E, Alarcón T, Kleer C, Menendez JA, Lupu R.Oncotarget. 2016 May 18. doi: 10.18632/oncotarget.9463. [Epub ahead of print] PMID:27223424
    • Cover Image, Volume 117, Number 6, June 2016.Hassan M, El Khattouti A, Ejaeidi A, Ma T, Day WA, Espinoza I, Vijayakumar S, Gomez CR.J Cell Biochem. 2016 Jun;117(6):i. doi: 10.1002/jcb.25562.PMID:27043249
    • Elevated Expression of Hepatoma Up-Regulated Protein Inhibits γ- Irradiation- Induced Apoptosis of Prostate Cancer Cells. Hassan M, El Khattouti A, Ejaeidi A, Ma T1, Day WA, Espinoza I, Vijayakumar S, Gomez CR. J Cell Biochem. 2016 Jun;117(6):1308-18. doi: 10.1002/jcb.25419. Epub 2015 Nov 17. PMID:26505164
    • Heregulin, a new interactor of the telosome/shelterin complex in human telomeres. Menendez JA, Benboudjema L, Vellon L, Rubio MA, Espinoza I, Campisi J, Lupu R. Oncotarget. 2015 Nov 24;6(37):39408-21. doi: 10.18632/oncotarget.4962. PMID:26327598
    • p53 Modulates Notch Signaling in MCF-7 Breast Cancer Cells by Associating with the Notch Transcriptional Complex via MAML1. J Cell Physiol.  Yun J, Espinoza I, Pannuti A, Romero D, Martinez L, Caskey M, Stanculescu A, Bocchetta M, Rizzo P, Band V, Band H, Kim HM, Park SK, Kang KW, Avantaggiati ML, Gomez CR, Golde T, Osborne B, Miele L. J. Cell Physiol. 2015 May 29. doi: 10.1002/jcp.25052. [Epub ahead of print]
    • Blockade of a key region in the extracellular domain inhibits HER2 dimerization and signaling. Menendez JA, Schroeder B, Peirce SK, Vellon L, Papadimitropoulou A, Espinoza I, Lupu R. J Natl Cancer Inst. 2015 Apr 16;107(6):djv090. doi: 10.1093/jnci/djv090. Print 2015 Jun.
    • CCN1 promotes vascular endothelial growth factor secretion through αvβ 3 integrin receptors in breast cancer. Espinoza I, Menendez JA, Kvp CM, Lupu R.  J Cell Commun Signal. 2014 Mar;8(1):23-7. doi: 10.1007/s12079-013-0214-6. Epub 2013 Dec 12.
    • Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition. Espinoza I, Pochampally R, Xing F, Watabe K, Miele L. Onco Targets Ther. 2013 Sep 6;6:1249-1259. Review. PMID:24043949[PubMed - as supplied by publisher] Free PMC
    • Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells, Espinoza I, Miele L. Cancer Lett. 2013 Nov 28;341(1):41-5. doi: 10.1016/j.canlet.2013.08.027. Epub 2013 Aug 21. Review. PMID:23973264[PubMed - indexed for MEDLINE]